Response to Neoadjuvant Treatment With Anti-Aromatase Anastrozole and Anti-Estrogen Fulvestrant: a Randomized Phase II Study in Postmenopausal Patients With Hormone-Sensitive Nonmetastatic Breast Cancer and an Exploratory Study of Molecular Signatures of Response.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Fulvestrant (Primary) ; Anastrozole
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms HORGEN
- 14 Jul 2015 Status changed from recruiting to completed, according to results published in the British Journal of Cancer.
- 14 Jul 2015 Results published in the British Journal of Cancer.
- 19 Mar 2014 Preliminary results presented at the 9th European Breast Cancer Conference.